CXS 299

Drug Profile

CXS 299

Alternative Names: CXS-299; DACH-Ac-Pt (IV); DACH-acetato-Pt; DAP

Latest Information Update: 02 Feb 2009

Price : $50

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer ChemGenex Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action DNA inhibitors; Mitosis inhibitors; Tumour suppressor protein p53 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Suspended Cancer

Most Recent Events

  • 02 Feb 2009 Suspended - Preclinical for Cancer in Australia (unspecified route)
  • 14 Jun 2007 Preclinical development is ongoing
  • 11 Feb 2005 Preclinical trials in Cancer in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top